

1 April 2026

## **US\$1.2m imaging data migration contract with Parkland Health**

- **Migration contract secured following a competitive tender for Vendor Neutral Archive replacement**
- **~90% of the contract's revenue is expected to be realised this calendar year.**
- **The third material contract signed in March 2026 which have a collective value of US\$2.95m**
- **Scope includes ~9m imaging studies, with expansion potential to ~13m**
- **The contract utilises Enlitic's AI-powered data management platform, Ensign, to standardise imaging data throughout the migration process**
- **Provides further validation of Enlitic's capability to deliver large-scale, complex enterprise imaging projects in the US healthcare system**
- **Positions Enlitic to capture potential follow-on revenue opportunities through expanded scope and broader platform adoption with a leading counterparty**

Enlitic, Inc. (ASX: ENL) is pleased to advise that, following a successful competitive proposal request, it has entered into an agreement with the Dallas County Hospital District, operating as Parkland Health in Texas, to provide migration services to support the replacement of Parkland Health's Vendor Neutral Archive.

Under the terms of the US\$1.2m contract, Enlitic will deliver imaging data migration and standardisation services across 9m legacy imaging studies. Data standardisation is a critical workstream that enables healthcare providers to convert inconsistent legacy imaging data into clean, structured and reconcilable datasets, unlocking downstream value across clinical workflows, analytics and AI deployment. Enlitic also has an opportunity to further expand the scope of the agreement to include up to 13m imaging studies, potentially delivering additional revenue.

The project will utilise Enlitic's AI-powered data management platform, Ensign, to standardise imaging data throughout the migration process, supporting the institution's data integrity and interoperability across the target archive.

The Ensign platform is an enterprise SaaS imaging solution that enables healthcare providers to efficiently access, manage and utilise large-scale medical imaging datasets, supporting streamlined workflows, improved interoperability and the deployment of advanced analytics and AI-driven applications.

Enlitic will also transfer existing imaging data from multiple systems into a single target archive, convert proprietary and non-digital imaging communication in medicine (DICOM) data into DICOM-compliant formats, and migrate related imaging orders and reports.

Approximately 90% of this contract's revenue is expected to be realised during the calendar year, supporting near-term revenue visibility. The agreement builds on recent commercial momentum, including a US\$1.5 million contract with Penn Medicine (refer ASX announcement: 23 March 2026) and a US\$250,000 agreement with St. Jude Children's Research Hospital, representing Enlitic's first entry into the paediatric healthcare sector (refer ASX announcement: 31 March 2026). Collectively, recent agreements reinforce growing third-party validation of Enlitic's platform from healthcare institutions directly and some of the world's leading sector OEMs.

**Enlitic CEO Michael Sistenich said:** *"Securing this agreement with Parkland Health through a competitive process is yet another strong validation of our end-to-end data migration and standardisation capabilities. Projects of this scale and complexity highlight the increasing need for healthcare providers to not only migrate legacy imaging data, but to ensure it is structured, interoperable and ready for long-term use within modern clinical environments.*

*Importantly, this engagement leverages our Ensight platform to deliver both migration and ongoing data optimisation, positioning Enlitic as more than a services provider and enabling us to support customers throughout the full lifecycle of their imaging data.*

*With the potential to expand the scope of this project, and a growing pipeline of similar opportunities, we are continuing to build momentum across the US market and demonstrate the value of our platform in large, enterprise healthcare settings, either directly with end customers or through the growing channel of OEM partners."*

**ENDS**

This announcement was authorised for release by the Board of Enlitic, Inc.

## **Enquiries**

### **Enlitic Investor Relations**

Australia:

[invest\\_au@enlitic.com](mailto:invest_au@enlitic.com)

### **Six Degrees Investor Relations**

Henry Jordan

[Henry.jordan@sdir.com.au](mailto:Henry.jordan@sdir.com.au)

+61 431 271 538

## About Enlitic

Enlitic is a software company that uses artificial intelligence to develop software products that manage medical imaging data in radiology (such as MRI, CT scans, X-ray and ultrasound images) and licences such products to healthcare providers. Enlitic's products (including its current product offering and product suite under development) seek to standardise, protect, integrate, and analyse data to create the foundation of a real-world evidence platform that can improve clinical workflows, increase efficiencies, and expand capacity. Read more at [enlitic.com](http://enlitic.com).

Enlitic's CDIs are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933 as amended, and in accordance with the procedures established pursuant to the provisions of a no action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this announcement.